PROCEPT BioRobotics Corporation (PRCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and followin ...

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics" or the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Delaware 26-0199180 (State or o ...

PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ago, beating the consensus loss of $(0.49). The surgical robotics company reported third-quarter sales of $58.4 million, up 66.3% year-over-year, beating the consensus of $53.18 million. The increase was primarily driven by increased system sales, higher average selling prices, and increased handpiece and other consumab ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaw ...

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.52 per share when it actually produced a loss of $0.50, delivering a surprise of 3.85%. Over the last four quarters, the com ...

| --- | --- | --- | |--------------------------------------------------------------|-------|-------| | | | | | | | | | VISION: BECOME THE BPH TREATMENT OF CHOICE FOR ALL PROSTATES | | | | October 2024 | | | Safe Harbor Statement This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipat ...

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance SAN JOSE, Calif., October 28, 2024 -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights • Total revenue of $58.4 million for the third quarter of 2024, an incre ...

Financial Performance - Total revenue for Q3 2024 was $58.4 million, a 66% increase compared to Q3 2023 [2][3] - U.S. revenue for Q3 2024 was $52.2 million, a 62% increase compared to Q3 2023 [3] - U.S. handpiece and consumables revenue for Q3 2024 was $29.6 million, a 74% increase compared to Q3 2023 [2][3] - U.S. system and rental revenue for Q3 2024 was $19.6 million, a 46% increase compared to Q3 2023 [2][3] - International revenue for Q3 2024 was $6.2 million, a 122% increase compared to Q3 2023 [2][3] - Gross margin for Q3 2024 was 63.2%, compared to 53.8% in Q3 2023 [4] - Net loss for Q3 2024 was $21.0 million, compared to a loss of $24.6 million in Q3 2023 [5] - Adjusted EBITDA for Q3 2024 was a loss of $12.4 million, compared to a loss of $19.4 million in Q3 2023 [5] Full Year 2024 Guidance - The company projects full year 2024 revenue to be in the range of $222.5 million to $223.0 million, representing 63% to 64% growth over 2023 [5][6] - Full year 2024 gross margin is projected to be approximately 61%, up from previous guidance of 59% [6] - Full year 2024 Adjusted EBITDA loss is projected to be $60.0 million, improved from previous guidance of $67.5 million [6] Operational Highlights - The company sold 45 robotic systems in the U.S. in Q3 2024 at an average selling price of approximately $432,000 [2] - As of September 30, 2024, the install base of robotic systems in the U.S. was 445 systems [3] - The company successfully launched HYDROS in Q3 2024 after receiving FDA clearance in August 2024 [2] Industry and Product Focus - PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care in urology [8] - The company manufactures the AQUABEAM® and HYDROS™ Robotic Systems, with HYDROS being the only AI-powered robotic technology delivering Aquablation therapy [8] - Aquablation therapy is designed to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [8] - The company has over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [8] Financial Position - Cash, cash equivalents, and restricted cash as of September 30, 2024, totaled $199.8 million [5] - Total current assets as of September 30, 2024, were $322.98 million, compared to $350.57 million as of December 31, 2023 [17] - Total liabilities as of September 30, 2024, were $132.92 million, compared to $123.97 million as of December 31, 2023 [18]

A downtrend has been apparent in PROCEPT BioRobotics Corporation (PRCT) lately with too much selling pressure. The stock has declined 15.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technic ...